In seven best-selling editions, Shara Rosen has provided a total view of every aspect of the market for in vitro diagnostic (IVD) testing in one complete volume. The report, The Worldwide Market for In Vitro Diagnostic Tests, is a testament to the Kalorama methodology. Real industry knowledge combined with an exhaustive review of the medical, business, and company literature. Market numbers for business planning matched with a discovery of the trends that are impacting the industry. A realistic forecast five years into the future for companies already participating in or considering entry into this growing industry. The idea behind Kalorama's unique report is that the entire market can be captured in one volume and business planners can use it as a key reference. Published every two years, this volume includes coverage of the most important aspects of all of the major segments of clinical lab testing, including:
For each of these sections, Shara Rosen reviews the key products dominating the market, the innovations that are occurring, and the trends that are impacting the segments. Market sizes, forecasts and shares are provided, as well as a geographic breakdown of the segments, where possible. Changes in technology development, regulatory and reimbursement issues, clinical care, and business environments are discussed. Current market numbers are presented for 2009, with projections given through 2014. Kalorama Information’s Report - ‘The Bible of the IVD Industry’ Many of the top IVD companies use this product for business planning, which means that this volume can provide a uniform standard for in vitro diagnostic market numbers. These are the numbers that it is very likely competitive companies will be using in their planning. This 900+ page edition greatly expands coverage of the field and tracks the most important developments. IVD is a worldwide business. While the US is a large healthcare market, much of the dynamism occurs in other areas. Many of the most interesting developments are occurring in emerging markets. As part of its coverage, the report breaks down the entire IVD market for the following regions.
In this seventh edition of The Worldwide Market for In Vitro Diagnostic Tests Kalorama Information has reorganized the presentation of the IVD market in a manner that better reflects how the industry has evolved.
The report covers companies that are established leaders in in vitro diagnostics, companies that dominate a specialty area and those that have very innovative or promising approaches. Over two hundred companies are profiled in the The Worldwide Market for In Vitro Diagnostics; among those companies profiled:
THE IVD INDUSTRY IN 2010 The IVD industry is on an upswing. For the past 15 years the number of assays introduced has been growing at a remarkable clip. At the same time, diagnostic laboratory technology is changing dramatically, due to the publication of the human genome project and advances in functional genomics, bioinformatics, miniaturization and microelectronics. Further the revolution in bioinformatics has allowed scientists to mine genetic information to derive new and hopefully better markers of some of the most pressing health problems such as cancer, cardiac disease, diabetes and autoimmune disorders. This has contributed to growth in many areas but especially in immunoassays and nucleic acid tests. However, these tests are being launched in a time of global economic instability and rising healthcare costs. The fact is most labs continue to run established tests that account for most of the lab’s human and financial resources. The only way to add new tests into the toolbox is to do more with the same amount of resources. And with the economic downturn, for most labs it may even mean doing more with less. There is also a lack of trained lab technologists, so there is a decreasing availability of human resources needed to run the more complex new set of molecular and histological tests and immunoassays. Therefore there has been a proliferation of test and lab automation tools launched that remove precious human resources from mundane pre-analytical and sample tracking tasks to make time for more sophisticated ones. This phenomenon was once thought to be the purview of biochemistry and immunoassays but automation is becoming a common feature in blood banking, microbiology, and histology. This emphasis on automation has created further consolidation of laboratory testing to large core labs. In 2010, systems for urinalysis, coagulation and microbiology are ready to take their place along side the hematology, chemistry and immunoassay instruments - all located in a single core lab. In larger labs they may be linked to a common track line. It has been some ten years since the Institute of Medicine (IOM) alerted healthcare professionals to the cost of medical errors. Most of these errors involve mistakes related to medications including administering or prescribing the wrong drug, providing the wrong dose, or using the wrong route to administer drugs to patients. But there also is an element of processing errors in the lab that include the wrong tests run on a patient sample, errors in entering a patient’s name, etc and not sending results in a timely manner. Thus barcoding, error checking and sample tracking via information systems have become a major tool to assure patient safety through a limitation of errors. Doing more with less appears to be a continuing theme. Automation and information systems are becoming the norm for hospital labs. In today’s depressed economy, these tools help labs control costs, reduce unnecessary spending, and get more for every dollar they spend. The trend applies to small and mid-sized hospital laboratories as well as high volume labs. For the first time, established automated technology considered normal in biochemistry and hematology is now a reality for microbiology.
Related Reports: The World Market for Orphan DrugsJun 13, 2013 - KLI5061933 - $4,500.00 Bioinformatics in IVD Testing Jun 7, 2013 - KLI5060494 - $1,995.00 Blood: The Worldwide Market for Blood Products, Blood Testing, Blood Equipment, and Synthetic Blood Products May 23, 2013 - KLI5053645 - $3,500.00 The World Market for Pain Management Drugs and Devices May 20, 2013 - KLI5042319 - $3,500.00 The World Market for Catheters (Cardiovascular, Urological, Intravenous and Specialty Devices) May 8, 2013 - KLI5040798 - $3,500.00 The World Market for Cancer Diagnostics, 5th Edition: Precision and Personalized Testing Arrives May 8, 2013 - KLI5036103 - $4,500.00 The Global Market for Medical Devices, 4th Edition May 1, 2013 - KLI5030825 - $1,995.00 The World Market for Dialysis Equipment and Services (United States, Japan, UK, Italy, India, China, Australia and Canada ) Apr 15, 2013 - KLI5019344 - $3,995.00 The U.S. Market for Urgent Care Centers Mar 22, 2013 - KLI5003148 - $2,500.00 Retail Clinics: Consumer Attitudes Results of the 2013 Kalorama Survey Mar 22, 2013 - KLI5007914 - $995.00 |
800.298.5603
Int'l: +1.240.747.3096
Questions?
Contact a research specialist >
Most Popular Research
The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 8th Edition
Results of The 2012 Kalorama IVD Procedure Count: White Paper
IVD Market Research Bundle (In Vitro Diagnostic Test Markets, BRIC and Other Regional Markets, Biomarker Testing and Other Pharmacodiagnostics)
White Paper: Animal Diagnostics: "Sister Market" to IVD?
The World Market for Point of Care (POC) Diagnostics
Why Epigenomics May Be a Game-Changer in Diagnostics and Pharmaceuticals
|
|||||||||
Email a colleague
Printer format
Order by fax|
Privacy Policy
|
Terms and Conditions
|
Site Map
|
Return Policy
|
Press
|
Help FAQs
|